Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Rhea-AI Summary
Coherus Oncology (Nasdaq: CHRS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will host a conference call and webcast starting at 5:00 p.m. Eastern Time on November 6, 2025 to discuss results and provide a business update.
Investors must pre-register for dial-in details and a PIN; a live webcast and an archived replay will be available on the company’s Investors website at https://investors.coherus.com. The press release and related materials will be posted on the same site before the call begins.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, CHRS declined 1.73%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $201M at that time.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, November 6, 2025, starting at 5:00 p.m. Eastern Standard Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI8cec893e4a1a4d98a4596ef8068cb4bd
Webcast: https://edge.media-server.com/mmc/p/d2g4jyb4
The press release with the third quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners’, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
Coherus Contact Information
Investors:
Carrie Graham
VP, Investor Relations and Advocacy
IR@coherus.com
FAQ
When will Coherus Oncology (CHRS) report third quarter 2025 results?
What time is the Coherus Oncology (CHRS) Q3 2025 conference call and webcast?
How can investors access the Coherus Oncology (CHRS) live call on November 6, 2025?
Where will the Coherus Oncology (CHRS) press release and slides be posted for Q3 2025?
Will a replay of the Coherus Oncology (CHRS) Q3 2025 webcast be available?
What should attendees do before joining the Coherus Oncology (CHRS) conference call?
